Global Awareness to Alzheimer’s Disease and Dementia

The global economic impact growth of IoT by the end of 2025 is estimated to be around $12.5 trillion with more than 100 billion connected IoT devices. Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential til 2025. IoT is expected to offer advanced connectivity of devices, systems, and services that goes beyond machine-to-machine (M2M) communications and covers a variety of protocols, domains, and applications. The interconnection of these embedded devices (including smart objects), is expected to usher in automation in nearly all fields, while also enabling advanced applications like a smart grid, and expanding to the areas such as smart cities.

Innovation for Alzheimer’s Disease and Dementia" which looked at ways to harness developments in life sciences and information technologies to accelerate innovation in the prevention and treatment of the disease. White paper reports on the opportunities offered by the informatics revolution and big data. No one nation has all the assets to pursue this type of research independently. This huge challenge, the OECD held a consultation on "Unlocking Global Collaboration to Accelerate Innovation for Alzheimer’s Disease and Dementia" which looked at ways to harness developments in life sciences and information technologies to accelerate innovation in the prevention and treatment of the disease

Changing growth supply and demand scenarios

website wordpress webhosting best company service free transfer files migration

The Alzheimer’s disease market is further segmented by geographical region as North America which includes The USA and Canada, Latin American countries such as Brazil, Argentina, Colombia, European countries such as The UK, France, Germany, Italy, Asia-Pacific countries such as Japan, China, India and Australia and for the Middle East & Africa countries are Saudi Arabia, UAE, Qatar, and South Africa. The economic and social impact of chronic brain disorders (CBD) such as Alzheimer’s disease (AD) and other neurodegenerative diseases will become the number one public health problem worldwide, directly affecting 100 million people by 2050. On-going demographic trends, namely aging populations worldwide, are leading to the unprecedented expansion of consumer demand for healthcare services. Healthcare systems worldwide soon will confront a serious crisis as a result of significant growth of the healthcare market

Evolving growth market trends and dynamics

More than 35 million people worldwide had dementia in 2010, when annual costs were estimated at USD 604 billion; the number of people with dementia is expected to exceed 115 million by 2050. Alzheimer’s disease is today considered the prototype problem for the Grand Global Challenge in healthcare. Despite decades of intensive research, the causal chain of mechanisms behind Alzheimer’s has remained elusive as reflected in recent failures of well-designed clinical trials on promising investigational new drugs. The multi-factorial nature of the disease requires the collection, storage, and processing of increasingly large and very heterogeneous datasets (behavioral, genetic, environmental, epigenetic, clinical data, brain imaging, etc.).

Key market growth segments and sub-segments

Alzheimer’s disease is a progressive, degenerative disorder that attacks the brain’s nerve cells, or neurons, resulting in loss of memory, thinking and language skills, and behavioral changes. According to our analysts, global Alzheimer’s’ disease market is estimated to be approximately $10 billion for the year 2016. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increase in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

The Government request also includes $70 million in new money for the cross agency BRAIN Initiative, more than doubling its NIH funding; $51 million more for Alzheimer’s disease research (a 9% increase over current spending); and $51 million more for vaccines against such diseases as HIV and influenza.

Alzheimer’s disease Therapeutics and Diagnostics market have been segmented by therapeutics, diagnostics, imaging technologies, and geography. The market by therapeutics includes biomarkers. Based on diagnostics the market has been segmented as brain imaging and blood tests. The market by imaging technologies includes structural imaging, functional imaging, and molecular imaging. The request also includes $70 million in new money for the cross-agency BRAIN Initiative, more than doubling its NIH funding; $51 million more for Alzheimer’s disease research (a 9% increase over current spending); and $51 million more for vaccines against such diseases as HIV and influenza

The cost of caring for Alzheimer’s patients in the U.S. is estimated to be $236 billion in 2016. (Alzheimer’s Association) The global cost of Alzheimer’s and dementia is estimated to be $605 billion, which is equivalent to 1% of the entire world’s gross domestic product. Medicare and Medicaid are expected to pay $154 billion in 2015 for healthcare, long-term care and hospice for people with Alzheimer’s and other dementias.

Studies indicate that such early detection is possible, but more research is needed before these techniques can be used routinely to diagnose Alzheimer’s disease in everyday medical practice.

Mild Alzheimer’s Disease
As Alzheimer’s disease progresses, people experience greater memory loss and other cognitive difficulties. Problems can include wandering and getting lost, trouble handling money and paying bills, repeating questions, taking longer to complete normal daily tasks, and personality and behavior changes. People are often diagnosed in this stage.

Moderate Alzheimer’s Disease
In this stage, damage occurs in areas of the brain that control language, reasoning, sensory processing, and conscious thought. Memory loss and confusion grow worse, and people begin to have problems recognizing family and friends. They may be unable to learn new things, carry out multistep tasks such as getting dressed or cope with new situations. In addition, people at this stage may have hallucinations, delusions, and paranoia and may behave impulsively.

Severe Alzheimer’s Disease
Ultimately, plaques and tangles spread throughout the brain, and brain tissue shrinks significantly. People with severe Alzheimer’s cannot communicate and are completely dependent on others for their care. Near the end, the person may be in bed most or all of the time as the body shuts down.

Scientists don’t yet fully understand what causes Alzheimer’s disease in most people. In people with early-onset Alzheimer’s, a genetic mutation may be the cause. Late-onset Alzheimer’s arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer’s may differ from person to person. Scientists are conducting studies to learn more about plaques, tangles, and other biological features of Alzheimer’s disease. Advances in brain imaging techniques allow researchers to see the development and spread of abnormal amyloid and tau proteins in the living brain, as well as changes in brain structure and function. Scientists are also exploring the very earliest steps in the disease process by studying changes in the brain and body fluids that can be detected years before Alzheimer’s symptoms appear. Findings from these studies will help in understanding the causes of Alzheimer’s and make diagnosis easier. One of the great mysteries of Alzheimer’s disease is why it largely strikes older adults. Research on normal brain aging is exploring this question. For example, scientists are learning how age-related changes in the brain may harm neurons and affect other types of brain cells to contribute to Alzheimer’s damage. These age-related changes include atrophy (shrinking) of certain parts of the brain, inflammation, vascular damage, production of unstable molecules called free radicals, and mitochondrial dysfunction (a breakdown of energy production within a cell).

Talk to your healthcare provider about local studies that may be right for you.
Contact Alzheimer’s disease research centers or memory or neurology clinics in your community.

About Zekel Healthcare, Mauris Griffin founder ZEHE (Healthcare) The Company, healthcare IT using digital ecosystems to drive innovation research in Alzheimer’s is a disease of the brain that causes problems with memory, thinking and behavior. The Internet of Things (IOT) is an ecosystem where multiple applications communicate with each other as a network. Alzheimer’s is the sixth-leading cause of death in the United States, and today of the 5.4 million Americans are living with the disease. Every 69 seconds, someone in America develops Alzheimer’s disease, and by mid-century someone will develop Alzheimer’s every 33 seconds. Listen to our podcasts AlzheimersQ, AlzheimersIQ, DementiaQ FibonC Element in English and Spanish AlzheimersQ Espanol, AlzheimersIQ de Alzheimer Espanol, Elemento FibonC, Alzheimers Virtual both on Apple Podcast, Google Podcast, Spotify, Tunein, Stitcher or on EKG Apple Watch Series 4, Android.

Leave a Reply